// App-Quantinova.ai

BSH19‐PO‐169 : Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial

Researchers

Presenter

  • M. Desborough

Principal Investigators

  • R. Al-Shahi Salman

  • S. Stanworth

  • D. Havard

  • P.M. Brennan

  • R. Dineen

  • T. Coats

  • P. Johnson

  • T. Hepburn

  • P. Bath

  • N. Sprigg

Medical Centers

  • Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, United Kingdom

  • Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom

  • Transfusion Medicine, NHS Blood and Transplant, Oxford, UK

  • Division of Clinical Neuroscience, University of Nottingham, Nottingham

  • Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

  • Patient representative

  • Clinical Trials Unit, University of Nottingham, Nottingham

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • Sex hormone binding globulin

  • von Willebrand factor

Drug/Treatment

  • rFVIIa

  • Tranexamic acid

  • Caprilon

  • Sochlor

  • Desmopressin

  • FVIII

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • NIHR and RfPB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved